Clinical Trials at New York Medical College
As of August 2026, 37 paid clinical trials are recruiting at New York Medical College, located at 15 DANA ROAD, BASIC SCIENCES BLDG ROOM C21, VALHALLA, NY 10595-1646, phone (914) 594-4730 in Valhalla, New York. Active studies at this site cover conditions such as Acute Myeloid Leukemia, ARDS and ARDS (Acute Respiratory Distress Syndrome). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Valhalla
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
38 clinical trials at New York Medical College
·Clear filters·A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Pompe Disease Registry Protocol
Fabry Disease Registry & Pregnancy Sub-registry
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Project: Every Child for Younger Patients With Cancer
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
CMV CTLs in Neonates With CMV Infection
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Common conditions studied in Valhalla
- Acute Myeloid Leukemia (5 active studies)
- ARDS (4 active studies)
- ARDS (Acute Respiratory Distress Syndrome) (4 active studies)
- Acute Respiratory Distress Syndrome (4 active studies)
- Acute Respiratory Distress Syndrome (ARDS) (4 active studies)
- Burkitt Lymphoma (4 active studies)
Leading research sponsors in Valhalla
- New York Medical College
- Children's Oncology Group
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
- PepsiCo Global R&D
Frequently asked questions
How many paid clinical trials are currently recruiting in Valhalla?
There are approximately 99 recruiting clinical trials in Valhalla, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Valhalla pay participants?
Most recruiting trials in Valhalla compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Valhalla?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Valhalla?
The most common conditions under active study in Valhalla include Acute Myeloid Leukemia (5), ARDS (4), ARDS (Acute Respiratory Distress Syndrome) (4), Acute Respiratory Distress Syndrome (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Valhalla?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Valhalla on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Valhalla?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Valhalla?
Recruiting research sites in Valhalla include New York Medical College, Westchester Medical Center, New York Medical College at Westchester Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Valhalla right now?
The largest active categories in Valhalla are Cancer & tumors (31), Cardiovascular (9), Neurology & pain (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of New York Medical College?
New York Medical College is located at 15 DANA ROAD, BASIC SCIENCES BLDG ROOM C21, VALHALLA, NY 10595-1646. Use the Google Maps link in the intro above to get directions.
How do I contact New York Medical College?
You can reach New York Medical College by phone at (914) 594-4730. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.